EUVIMEDEUVIMED entdecken
Crossref

Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis

Laurent Lam iD, Patrizia Carrieri, Gilles Hejblum, Jonathan Bellet, Marc Bourlière, Fabrice Carrat

Liver International · 2024

DOI: 10.1111/liv.15872 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Laurent Lam und 5 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The economic impact of managing patients with hepatitis C virus (HCV) infection remains unknown. This study aimed to assess the economic burden of chronic HCV infection from a national health insurance perspective and the impact of direct‐acting antivirals (DAAs) using nationwide real‐world data.

Methods

Patients with chronic HCV infection were identified from the French Health Insurance Claims Databases (SNDS) and matched for age and sex to the general population. Health resource utilization and reimbursements were summarized according to healthcare expenditure items from 2012 to 2021. The economic burden attributable to chronic HCV infection was evaluated over a 10‐year period. Finally, the impact of DAAs was estimated using economic data derived from the SNDS.

Results

A total of 145 187 patients with chronic HCV infection were identified. Among the patients eligible for DAA therapy, 81.5% had received DAA by the end of 2021. Over a 10‐year period, managing patients with chronic HCV infection resulted in an additional cost of €9.71 billion (95% confidence interval [CI]: €9.66–€9.78 billion) or €9191 (95% CI: €9134–€9252) per patient per year compared to the general population. After DAA therapy, patients with chronic HCV infection had a higher economic burden than the general population, with an additional cost of €5781 (95% CI: €5540–€6028) per patient at the fifth‐year post‐DAA therapy.

Conclusions

A significant economic burden persists among patients with HCV infection after DAA treatment. The high proportion of patients not treated with DAA therapy supports reinforcing policies for universal access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicHepatitis CHumansAntiviral AgentsHepacivirusFinancial StressFranceData Analysis

Stichwörter der Autor:innen

administrative claimsantiviral agentschronichealthcarehealthcare costshepatitis C

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, IPLESP, Sorbonne Université, Paris, France.
  • INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, Aix Marseille Univ, Marseille, France.
  • Department of Hepatology and Gastroenterology, Hôpital Saint Joseph, Marseille, France.
  • INSERM, UMR 1252 IRD SESSTIM, Aix Marseille Université, Marseille, France.
  • Department of Public Health, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, Sorbonne Université, Paris, France.

ORCID-Profile: Laurent Lam

Zitieren

APA

Lam, L., Carrieri, P., Hejblum, G., Bellet, J., Bourlière, M., & Carrat, F. (2024). Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis. Liver International. https://doi.org/10.1111/liv.15872

Vancouver

Lam L, Carrieri P, Hejblum G, Bellet J, Bourlière M, Carrat F. Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis. Liver International. 2024. doi:10.1111/liv.15872

BibTeX
@article{Lam2024,
  author = {Lam, Laurent and Carrieri, Patrizia and Hejblum, Gilles and Bellet, Jonathan and Bourlière, Marc and Carrat, Fabrice},
  title = {Real‐world economic burden of hepatitis C and impact of direct‐acting antivirals in France: A nationwide claims data analysis},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.15872}
}
Kostenlos starten →